Nasdaq

SAB BIO Reports Positive Phase 1 Trial Results for SAB-142 in Type 1 Diabetes, Supporting Advancement to Phase 2b Development

SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
Nasdaq

SAB Biotherapeutics Gets FDA Clearance To Advance Phase 1 Trial Of SAB-142 In Type-1 Diabetes

(RTTNews) - SAB Biotherapeutics, Inc. (SABS) announced on Tuesday that the FDA has granted clearance for an investigational new drug application to advance its phase 1 clinical trial of SAB-142 for ...
Hosted on MSN

Sab Biotherapeutics’ New Study Targets Type 1 Diabetes Progression

Sab Biotherapeutics, Inc. ((SABS)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...